Evolus, Inc.

NasdaqGM EOLS

Evolus, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 248.33 M

Evolus, Inc. Revenue is USD 248.33 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 34.93% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Evolus, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 184.04 M, a 31.81% change year over year.
Evolus, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 139.63 M, a 63.13% change year over year.
Evolus, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 85.59 M, a 54.47% change year over year.
Evolus, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 55.41 M, a 257.99% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqGM: EOLS

Evolus, Inc.

CEO	Mr. David Moatazedi
IPO Date	Feb. 8, 2018
Location	United States
Headquarters	520 Newport Center Drive
Employees	322
Sector	Consumer Discretionary
Industries Cosmetics Biotechnology Pharmaceuticals

Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Key trends

Past 5 years